As of June 2026, according to Pacira BioSciences's latest financial report, the company's current EPS (TTM) is $0.12. In 2025, the company recorded an earnings per share (EPS) of $0.16, which represents an increase compared to its EPS of -$2.15 in 2024. Pacira BioSciences's earnings per share for the quarterly report ending on Mar 31, 2026 was $0.07.
The annual EPS in 2025 was $0.16, an increase of 107.4% from -$2.15 in 2024. For the quarter ending Mar 31, 2026, the EPS was $0.07, showing a 30% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $0.12. In 2024, the annual EPS was -$2.15, showing a decrease of 336.3% from 2023.
Pacira BioSciences has recorded a decrease in EPS of 30% over the last 12 months (YoY, quarterly). For the last three years, PCRX recorded an average annual EPS growth rate of -23%. Pacira BioSciences had an average annual EPS growth rate of -45.8% over the last 5 years. Across the last decade, PCRX had an average annual EPS growth of 12.3%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| OMER Omeros Corp | 7.88 | 98.1% | N/A | N/A |
| PCRX Pacira BioSciences Inc | 188.92 | 107.4% | -23% | -45.8% |
| HRTX Heron Therapeutics Inc | N/A | -33.3% | N/A | N/A |
| CPIX Cumberland Pharmaceuticals Inc | N/A | 58.7% | N/A | N/A |
| TVRD Tvardi Therapeutics Inc. | N/A | 78.5% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.